Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 2
1981 1
1982 2
1986 1
1988 3
1989 1
1991 3
1992 3
1994 2
1995 4
1996 5
1997 3
1998 6
1999 8
2000 9
2001 11
2002 10
2003 16
2004 17
2005 13
2006 20
2007 21
2008 33
2009 40
2010 36
2011 29
2012 38
2013 51
2014 66
2015 88
2016 84
2017 89
2018 105
2019 111
2020 129
2021 193
2022 199
2023 190
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

1,483 results

Results by year

Filters applied: . Clear all
Page 1
Monoclonal antibody therapies against SARS-CoV-2.
Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Focosi D, et al. Lancet Infect Dis. 2022 Nov;22(11):e311-e326. doi: 10.1016/S1473-3099(22)00311-5. Epub 2022 Jul 5. Lancet Infect Dis. 2022. PMID: 35803289 Free PMC article. Review.
In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omic …
In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outco …
Tezepelumab for asthma.
Nolasco S, Pelaia C, Scioscia G, Campisi R, Crimi C. Nolasco S, et al. Drugs Today (Barc). 2022 Dec;58(12):591-603. doi: 10.1358/dot.2022.58.12.3449205. Drugs Today (Barc). 2022. PMID: 36651067 Review.
In this regard, tezepelumab (AMG-157/MEDI-9929), a TSLP-targeted first-in-class fully human monoclonal antibody, has been shown in phase II and III studies to be effective and safe in treating patients with severe asthma, regardless of the underlying endotype or phenotype and irr …
In this regard, tezepelumab (AMG-157/MEDI-9929), a TSLP-targeted first-in-class fully human monoclonal antibody, has been shown in phase II …
Prenatal Nonstress Test.
Umana OD, Siccardi MA. Umana OD, et al. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30725808 Free Books & Documents.
Interpretation of the nonstress test follows a systematic approach to include: the baseline fetal heart rate, baseline fetal heart rate variability, presence of accelerations, decelerations, and contractions....
Interpretation of the nonstress test follows a systematic approach to include: the baseline fetal heart rate, baseline fetal h …
Concussion Baseline Retesting Is Necessary When Initial Scores Are Low.
Fraser MA, Kilchrist LM, Kuo M. Fraser MA, et al. Clin J Sport Med. 2022 Jan 1;32(1):e40-e51. doi: 10.1097/JSM.0000000000000872. Clin J Sport Med. 2022. PMID: 33239512
OBJECTIVE: To determine whether (1) initial baseline scores are significantly better for those who have valid (initial valid) versus invalid scores (initial invalid) on their concussion baseline testing, (2) retesting results in significantly improved baseline …
OBJECTIVE: To determine whether (1) initial baseline scores are significantly better for those who have valid (initial valid) versus …
1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study.
von Bardeleben RS, Mahoney P, Morse MA, Price MJ, Denti P, Maisano F, Rogers JH, Rinaldi M, De Marco F, Rollefson W, Chehab B, Williams M, Leurent G, Asch FM, Rodriguez E. von Bardeleben RS, et al. JACC Cardiovasc Interv. 2023 Nov 13;16(21):2600-2610. doi: 10.1016/j.jcin.2023.09.029. Epub 2023 Oct 24. JACC Cardiovasc Interv. 2023. PMID: 37877913 Free article.

At 1 year, there was a durable reduction in MR to mild or less in 92.6% and to none or trace in 44.2% (P < 0.0001 vs baseline). Few subjects had major adverse events through 1 year (<2% for myocardial infarction, surgical reintervention, or single-leaflet device atta

…

At 1 year, there was a durable reduction in MR to mild or less in 92.6% and to none or trace in 44.2% (P < 0.0001 vs baseline). Fe

…
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.
Di Marco T, Scammell TE, Meinel M, Seboek Kinter D, Datta AN, Zammit G, Dauvilliers Y. Di Marco T, et al. CNS Drugs. 2023 Jul;37(7):639-653. doi: 10.1007/s40263-023-01020-9. Epub 2023 Jul 21. CNS Drugs. 2023. PMID: 37477771 Free PMC article. Clinical Trial.
We analyzed polysomnography data for daridorexant 25 and 50 mg, zolpidem 10 mg, and placebo groups. Polysomnography was conducted at baseline, then on Days 1/2, 15/16, and 28/29 in the phase II study, and Months 1 and 3 in the phase III study. ...
We analyzed polysomnography data for daridorexant 25 and 50 mg, zolpidem 10 mg, and placebo groups. Polysomnography was conducted at base …
Characterization of Austrian severe asthma patients.
Renner A, Stoshikj S, Pohl W, Bal C, Reisinger M, Löffler-Ragg J, Zacharasiewicz A, Buhl R, Hamelmann E, Taube C, Korn S, Idzko M. Renner A, et al. Respir Med. 2023 Nov-Dec;219:107427. doi: 10.1016/j.rmed.2023.107427. Epub 2023 Oct 10. Respir Med. 2023. PMID: 37827294 Free article.
At the time of baseline visit, 23.4% of all patients had regular treatment with oral corticosteroids. Furthermore, 23.9% had received any severe asthma monoclonal antibody prior to the baseline visit. There were no notable differences in baseline characterist …
At the time of baseline visit, 23.4% of all patients had regular treatment with oral corticosteroids. Furthermore, 23.9% had received …
Dermato-allergological risks in beauty operators.
Lauriola MM, Corazza M. Lauriola MM, et al. Ital J Dermatol Venerol. 2023 Jun;158(3):243-248. doi: 10.23736/S2784-8671.23.07389-9. Epub 2023 May 10. Ital J Dermatol Venerol. 2023. PMID: 37162243
Young women are mainly affected, with the most affected sites being the hands. Anamnesis, patch tests with the baseline, integrative series, and use products are important to understand possible sensitization. ...
Young women are mainly affected, with the most affected sites being the hands. Anamnesis, patch tests with the baseline, integrative …
Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.
Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sassera D, De Marco L, Girello A, Mondelli MU, Baldanti F. Paolucci S, et al. Sci Rep. 2017 Nov 22;7(1):16017. doi: 10.1038/s41598-017-15987-1. Sci Rep. 2017. PMID: 29167469 Free PMC article.
Direct sequencing of HCV genes was performed at breakthrough in all 31 patients failing DAAs, and in 19 baseline patients. Deep sequencing analysis was performed in 15/19 baseline patients. ...Deep sequencing analysis showed RASs at baseline in 10/15 treatmen …
Direct sequencing of HCV genes was performed at breakthrough in all 31 patients failing DAAs, and in 19 baseline patients. Deep seque …
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.
Patruno C, Fabbrocini G, Lauletta G, Boccaletti V, Colonna C, Cavalli R, Neri I, Ortoncelli M, Schena D, Stingeni L, Hansel K, Piccolo V, Di Brizzi V, Potenza C, Tolino E, Bianchi L, Manti S, De Pasquale R, Di Lernia V, Caminiti L, Galli E, Coppo P, Chiricozzi A, De Simone C, Guerriero C, Amoruso FG, Provenzano E, Leonardi S, Licari A, Marseglia GL, Palermo A, Di Pillo S, Russo D, Moschese V, Patella V, Peduto T, Ferreli C, Zangari P, Veronese F, Berti SF, Gruber M, Pezzolo E, Termine S, Satta R, Dragoni F, Esposito M, Fargnoli MC, Chiodini P, Vallone Y, di Vico F, Picone V, Napolitano M. Patruno C, et al. J Dermatolog Treat. 2023 Dec;34(1):2246602. doi: 10.1080/09546634.2023.2246602. J Dermatolog Treat. 2023. PMID: 37580895 Free article.
Treatment effect was determined as overall disease severity, using EASI, P-NRS, S-NRS and c-DLQI at baseline, W16, W24, and W52. Ninety-six AD children diagnosed with moderate-to-severe AD and treated with dupilumab were enrolled.Results: Ninety-one (94.8%) patients comple …
Treatment effect was determined as overall disease severity, using EASI, P-NRS, S-NRS and c-DLQI at baseline, W16, W24, and W52. Nine …
1,483 results